Mixed Results From Retinopathy Prevention Trial

Mixed Results From Retinopathy Prevention Trial

Prophylactic anti-VEGF therapy with aflibercept (Eylea) slowed the progression of diabetic leer illness but did no longer sustain visible acuity any better than deferred treatment, a randomized trial confirmed. After 2 years of apply-up, sufferers randomized to aflibercept had a…